drugset / Trial / NCT00977444

Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment

NCT00977444

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.

Timeline

Start
2007-11
Primary completion
2009-02
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 8 mg/ml Other
Subject calcium gluconate Small molecule Other
Subject sodium bicarbonate Diagnostic / imaging agent Other

Indications